Overview

Kyverna Therapeutics develops cell therapies for autoimmune diseases. The company uses synthetic biology, immunology, and cell engineering to create engineered T cells designed to target and modulate the root causes of autoimmunity. Its therapies are intended to be given by a single infusion to achieve long-lasting disease control, reducing or eliminating the need for ongoing treatments. Kyverna pursues in-licensing and collaboration opportunities to broaden its technology and capabilities and to advance its therapies toward patients through development and sales to patients and healthcare providers. The core goal is to provide durable, well-tolerated treatments that can offer substantial, long-term relief for people with autoimmune diseases.